BMS Receives the CHMP’s Positive Opinion for Abecma (idecabtagene vicleucel) to Treat Multiple Myeloma
Shots:
- The CHMP positive opinion was based on the results from the P-III (KarMMa-3) clinical trial evaluating Abecma vs standard regimens in patients with r/r multiple myeloma following 2-4 prior lines of therapy. The 1EP of the study was PFS & 2EPs were ORR & OS
- Following a median follow-up of 30.9mos., the study showed a PFS of 13.8mos. vs 4.4mos., depicting a 51% reduction in risk of disease progression or deah with Abecma, along with an ORR of 71% vs 41% with CR in 44% vs 5%. The results were presented at the ASH Annual Meeting in Dec 2023
- Abecma is a CAR T cell therapy that functions by recognizing & binding to the surface of multiple myeloma cells & thereby causing CAR T cell proliferation, cytokine secretion & subsequent cytolytic killing of BCMA-expressing cells
Ref: BMS | Image: BMS
Related News:- BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
